---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-027535"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T07:54:00.451415+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Insmed Announces Positive Topline Results from Phase 3 ASPEN Study of Brensocatib in Bronchiectasis

## Summary
- ASPEN Phase 3 met primary endpoint: brensocatib 10mg and 25mg reduced annualized pulmonary exacerbations by 21.1% (p=0.0019) and 19.4% (p=0.0046) vs placebo.
- Brensocatib achieved statistical significance on multiple secondary endpoints including prolongation of time to first PE and odds of remaining exacerbation-free.
- Insmed plans to file NDA with FDA in Q4 2024; anticipates U.S. launch mid-2025, Europe/Japan launches first half 2026.
- If approved, brensocatib would be first approved treatment for bronchiectasis and first DPP1 inhibitor for neutrophil-mediated diseases.
- Brensocatib well-tolerated; severe TEAEs occurred in 12.7% (10mg), 11.7% (25mg), and 16.0% (placebo) with lower serious TEAE rates than placebo.

## SEC filing metadata
- accession: 0001140361-24-027535
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036124027535/0001140361-24-027535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036124027535/ef20030032_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-027535
- JSON: https://secwatch.observer/filing/0001140361-24-027535.json
- Plain text: https://secwatch.observer/filing/0001140361-24-027535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.